The effect of prophylactic peripapillary administration of methylprednisolone in reducing the risk and severity of postendoscopic retrograde cholangiopancreatography pancreatitis: A double blind clinical trial

Background : The most common complication of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP) is acute pancreatitis. A number of therapeutic trials have been studied due to reduce the occurrence of postendoscopic retrograde cholangiopancreatography pancreatitis (PEP)...

Full description

Bibliographic Details
Main Authors: Ahmad Shavakhi, Mahsa Khodadustan, Babak Tamizifar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-01-01
Series:Journal of Research in Medical Sciences
Subjects:
Online Access:http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2015;volume=20;issue=9;spage=850;epage=854;aulast=Shavakhi
_version_ 1811240859828486144
author Ahmad Shavakhi
Mahsa Khodadustan
Babak Tamizifar
author_facet Ahmad Shavakhi
Mahsa Khodadustan
Babak Tamizifar
author_sort Ahmad Shavakhi
collection DOAJ
description Background : The most common complication of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP) is acute pancreatitis. A number of therapeutic trials have been studied due to reduce the occurrence of postendoscopic retrograde cholangiopancreatography pancreatitis (PEP) but many of them were unsuccessful. Periampullary corticosteroid injection was proposed to use as prophylactic agents for PEP because of its anti-inflammatory property with relative low systemic side effects. Materials and Methods : By conducting a double blinded clinical trial study in a single center university hospital, all patients undergoing therapeutic or diagnostic ERCP in our gastrointestinal endoscopy ward, enrolled the study. During ERCP, we randomly assigned the patients in blocks of 40 to undergo a locally injection of methylprednisolone acetate (corticosteroid group) or saline (control group) on the major papilla and prospectively evaluated the occurrence of PEP pancreatitis in each groups. Clinical and laboratory findings of acute pancreatitis were collected by means of a validated questionnaire during the procedure and before discharge. At baseline and end of the study, were compared pancreatitis prevalence and also its severity by using Chi-square and t-test statistics. Results : The frequency of moderate to severe PEP pain was not significantly between the placebo and corticosteroid receiving group (13.7% ± 3.2% vs. 9.3% ± 2.1%, respectively; P = 0.8). There is no significant difference in the mean concentration of lipase and amylase between corticosteroid receiving group and placebo receiving group at the first, second, and third time. In the corticosteroid receiving group, 3 patients (10.3%) while in the control group, 11 patients (11.3%) developed pancreatitis. Conclusion: We found no significant difference in PEP rates and also severity between the corticosteroid and placebo groups. The mean increase in serum amylase and amylase level in pancreatitis patients and the frequency of abdominal pain were not significantly higher in the placebo group. Besides, there were no cases of severe PEP pancreatitis in either group.
first_indexed 2024-04-12T13:27:18Z
format Article
id doaj.art-6e0d1c66f61e42079c584de3388091df
institution Directory Open Access Journal
issn 1735-1995
1735-7136
language English
last_indexed 2024-04-12T13:27:18Z
publishDate 2015-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Research in Medical Sciences
spelling doaj.art-6e0d1c66f61e42079c584de3388091df2022-12-22T03:31:17ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362015-01-0120985085410.4103/1735-1995.170599The effect of prophylactic peripapillary administration of methylprednisolone in reducing the risk and severity of postendoscopic retrograde cholangiopancreatography pancreatitis: A double blind clinical trialAhmad ShavakhiMahsa KhodadustanBabak TamizifarBackground : The most common complication of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP) is acute pancreatitis. A number of therapeutic trials have been studied due to reduce the occurrence of postendoscopic retrograde cholangiopancreatography pancreatitis (PEP) but many of them were unsuccessful. Periampullary corticosteroid injection was proposed to use as prophylactic agents for PEP because of its anti-inflammatory property with relative low systemic side effects. Materials and Methods : By conducting a double blinded clinical trial study in a single center university hospital, all patients undergoing therapeutic or diagnostic ERCP in our gastrointestinal endoscopy ward, enrolled the study. During ERCP, we randomly assigned the patients in blocks of 40 to undergo a locally injection of methylprednisolone acetate (corticosteroid group) or saline (control group) on the major papilla and prospectively evaluated the occurrence of PEP pancreatitis in each groups. Clinical and laboratory findings of acute pancreatitis were collected by means of a validated questionnaire during the procedure and before discharge. At baseline and end of the study, were compared pancreatitis prevalence and also its severity by using Chi-square and t-test statistics. Results : The frequency of moderate to severe PEP pain was not significantly between the placebo and corticosteroid receiving group (13.7% ± 3.2% vs. 9.3% ± 2.1%, respectively; P = 0.8). There is no significant difference in the mean concentration of lipase and amylase between corticosteroid receiving group and placebo receiving group at the first, second, and third time. In the corticosteroid receiving group, 3 patients (10.3%) while in the control group, 11 patients (11.3%) developed pancreatitis. Conclusion: We found no significant difference in PEP rates and also severity between the corticosteroid and placebo groups. The mean increase in serum amylase and amylase level in pancreatitis patients and the frequency of abdominal pain were not significantly higher in the placebo group. Besides, there were no cases of severe PEP pancreatitis in either group.http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2015;volume=20;issue=9;spage=850;epage=854;aulast=ShavakhiCorticosteroidendoscopic retrograde cholangiopancreatographypancreatitispapillary edema
spellingShingle Ahmad Shavakhi
Mahsa Khodadustan
Babak Tamizifar
The effect of prophylactic peripapillary administration of methylprednisolone in reducing the risk and severity of postendoscopic retrograde cholangiopancreatography pancreatitis: A double blind clinical trial
Journal of Research in Medical Sciences
Corticosteroid
endoscopic retrograde cholangiopancreatography
pancreatitis
papillary edema
title The effect of prophylactic peripapillary administration of methylprednisolone in reducing the risk and severity of postendoscopic retrograde cholangiopancreatography pancreatitis: A double blind clinical trial
title_full The effect of prophylactic peripapillary administration of methylprednisolone in reducing the risk and severity of postendoscopic retrograde cholangiopancreatography pancreatitis: A double blind clinical trial
title_fullStr The effect of prophylactic peripapillary administration of methylprednisolone in reducing the risk and severity of postendoscopic retrograde cholangiopancreatography pancreatitis: A double blind clinical trial
title_full_unstemmed The effect of prophylactic peripapillary administration of methylprednisolone in reducing the risk and severity of postendoscopic retrograde cholangiopancreatography pancreatitis: A double blind clinical trial
title_short The effect of prophylactic peripapillary administration of methylprednisolone in reducing the risk and severity of postendoscopic retrograde cholangiopancreatography pancreatitis: A double blind clinical trial
title_sort effect of prophylactic peripapillary administration of methylprednisolone in reducing the risk and severity of postendoscopic retrograde cholangiopancreatography pancreatitis a double blind clinical trial
topic Corticosteroid
endoscopic retrograde cholangiopancreatography
pancreatitis
papillary edema
url http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2015;volume=20;issue=9;spage=850;epage=854;aulast=Shavakhi
work_keys_str_mv AT ahmadshavakhi theeffectofprophylacticperipapillaryadministrationofmethylprednisoloneinreducingtheriskandseverityofpostendoscopicretrogradecholangiopancreatographypancreatitisadoubleblindclinicaltrial
AT mahsakhodadustan theeffectofprophylacticperipapillaryadministrationofmethylprednisoloneinreducingtheriskandseverityofpostendoscopicretrogradecholangiopancreatographypancreatitisadoubleblindclinicaltrial
AT babaktamizifar theeffectofprophylacticperipapillaryadministrationofmethylprednisoloneinreducingtheriskandseverityofpostendoscopicretrogradecholangiopancreatographypancreatitisadoubleblindclinicaltrial
AT ahmadshavakhi effectofprophylacticperipapillaryadministrationofmethylprednisoloneinreducingtheriskandseverityofpostendoscopicretrogradecholangiopancreatographypancreatitisadoubleblindclinicaltrial
AT mahsakhodadustan effectofprophylacticperipapillaryadministrationofmethylprednisoloneinreducingtheriskandseverityofpostendoscopicretrogradecholangiopancreatographypancreatitisadoubleblindclinicaltrial
AT babaktamizifar effectofprophylacticperipapillaryadministrationofmethylprednisoloneinreducingtheriskandseverityofpostendoscopicretrogradecholangiopancreatographypancreatitisadoubleblindclinicaltrial